The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

References

• Mitsudomi T, Yatabe Y. 2007. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98(12):1817–1824. doi:10.1111/j.1349-7006.2007.00607.x.
   PubMed Web of Science ®Google Scholar
• Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, et al. 2008. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clinl Oncol. 26(34):5589–5595. doi:10.1200/JCO.2008.16.7254.
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al. 2012. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13(5):528–538. doi:10.1016/S1470-2045(12)70087-6.
   PubMed Web of Science ®Google Scholar
• Stasi I, Cappuzzo F. 2014. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Transl Respir Med. 2:2. doi:10.1186/2213-0802-2-2.
   PubMedGoogle Scholar
• Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al. 2015. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 372(18):1689–1699. doi:10.1056/NEJMoa1411817.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D, et al. 2007. ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 97(11):1560–1566. doi:10.1038/sj.bjc.6604068.
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304(5676):1497–1500. doi:10.1126/science.1099314.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. 2013. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thoracic Oncol. 8(1):118–122. doi:10.1097/JTO.0b013e3182781e35.
   Web of Science ®Google Scholar
• Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. 2011. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 17(11):3812–3821. doi:10.1158/1078-0432.CCR-10-3408.
   PubMed Web of Science ®Google Scholar
• Li K, Yang M, Liang N, Li S. 2017. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: perplexity and solution (Review). Oncol Rep. 37(3):1347–1358. doi:10.3892/or.2017.5409.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, et al. 2015. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 87(2):169–175. doi:10.1016/j.lungcan.2014.12.009.
   PubMed Web of Science ®Google Scholar
• Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, et al. 2017. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 114:96–102. doi:10.1016/j.lungcan.2017.11.005.
   PubMed Web of Science ®Google Scholar
• Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. 2014. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol. 19(4):594–600. doi:10.1007/s10147-013-0602-1.
   PubMed Web of Science ®Google Scholar
• Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al. 2004. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 10(24):8195–8203. doi:10.1158/1078-0432.CCR-04-1245.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K, Osada H, Imaizumi K, Hasegawa Y, Shimokata K, et al. 2006. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci. 97(8):753–759. doi:10.1111/j.1349-7006.2006.00233.x.
   PubMed Web of Science ®Google Scholar
• Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, Sommer SS. 2008. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene. 27(31):4336–4343. doi:10.1038/onc.2008.71.
   PubMed Web of Science ®Google Scholar
• Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, et al. 2014. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals Oncol. 25(1):126–131. doi:10.1093/annonc/mdt418.
   PubMed Web of Science ®Google Scholar
• Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP. 2009. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 8(8):2142–2151. doi:10.1158/1535-7163.MCT-08-1219.
   PubMed Web of Science ®Google Scholar
• Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, et al. 2015. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 16(7):830–838. doi:10.1016/S1470-2045(15)00026-1.
   PubMed Web of Science ®Google Scholar
• Wu JY, Shih JY. 2016. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. Onco Targets Ther. 9:6137–6145. doi:10.2147/OTT.S118071.
   PubMed Web of Science ®Google Scholar
• Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP. 2013. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Exp Lung Res. 39(8):328–335. doi:10.3109/01902148.2013.819535.
   PubMed Web of Science ®Google Scholar
• Lu RL, Hu CP, Yang HP, Li YY, Gu QH, Wu L. 2014. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma. Pathol Oncol Res. 20(2):445–451. doi:10.1007/s12253-013-9715-0.
   PubMed Web of Science ®Google Scholar
• Li M, Zhao BR, Liu SQ, An J, Deng PB, Han-Zhang H, Ye JY, Mao XR, Chuai SK, Hu CP. 2018. Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma. Cancer Biol Ther. 19(10):898–903. doi:10.1080/15384047.2018.1480296.
   PubMed Web of Science ®Google Scholar
• Cao L, Long L, Li M, Yang H, Deng P, Mao X, Xiang J, Li B, Zhang T, Hu C. 2018. The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. Onco Targets Ther. 11:2637–2646. doi:10.2147/OTT.S155995.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Deng Z, Yin J, Wang S, Lu D, Wen X, Li X, Xiao D, Hu C, Chen X, et al. 2017. The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy. Int J Cancer. 141(11):2336–2347. doi:10.1002/ijc.30921.
   PubMed Web of Science ®Google Scholar